Health Disparities in Endometrial Cancer

CE / CME

Identifying and Resolving Health Disparities in Endometrial Cancer Care for Black Women

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 29, 2023

Expiration: August 28, 2024

Ebony Hoskins
Ebony Hoskins, MD
Ritu Salani
Ritu Salani, MD, MBA

Activity

Progress
1
Course Completed

References

  1. Surveillance, Epidemiology, and End Results (SEER). Cancer stat facts: uterine cancer. seer.cancer.gov/statfacts/html/corp.html. Accessed August 11, 2023.
  2. Mahdy H, Casey MJ, Crotzer D. Endometrial cancer. ncbi.nlm.nih.gov/books/NBK525981. Accessed August 11, 2023.
  3. Clarke MA, Devesa SS, Harvey SV, et al. Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. J Clin Oncol. 2019;37:1895-1908.
  4. Zhang L, Kwan SY, Wong KK, et al. Pathogenesis and clinical management of uterine serous carcinoma. Cancers (Basel). 2020;12:686.
  5. Nemani D, Mitra N, Guo M, et al. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111:82-88.
  6. Abdulfatah E, Sakr S, Thomas S, et al. Clear cell carcinoma of the endometrium: evaluation of prognostic parameters in a multi-institutional cohort of 165 cases. Int J Gynecol Cancer. 2017;27:1714-1721.
  7. Hamilton SN, Tinker AV, Kwon J, et al. Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma. J Gynecol Oncol. 2022;33:e25.
  8. American Cancer Society. Cancer facts & figures 2023. cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html. Accessed August 11, 2023.
  9. Post CCB, Stelloo E, Smit VTHBM, et al. Prevalence and prognosis of Lynch syndrome and sporadic mismatch repair deficiency in endometrial cancer. J Natl Cancer Inst. 2021;113:1212-1220.
  10. Ryan NAJ, Glaire MA, Blake D, et al. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med. 2019;21:2167-2180.
  11. Eakin CM, Liao CI, Salani R, et al. The association of obesity with type I uterine cancer-is this an oversimplification?. Am J Obstet Gynecol. 2022;227:538-539.
  12. Eakin C, Lai T, Cohen, J. Alarming trends and disparities in high-risk endometrial cancer. Curr Opin Gynecol Obstet. 2023;35:15-20.
  13. Bredin HK, Krakstad C, Hoivik EA. PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: a systematic review and meta-analysis. PLoS One. 2023;18:e0283203.
  14. Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016;35:575-588.
  15. Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018;17:115.
  16. Taylor SE, O'Connor CM, Wang Z, et al. The highly recurrent PP2A Aα-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis. Cancer Res. 2019;79:4242-4257.
  17. Henley SJ, Miller JW, Dowling NF, et al. Uterine cancer incidence and mortality—United States, 1999-2016. MMWR Morb Mortal Wkly Rep. 2018;67:1333-1338.
  18. Harvey SV, Wentzensen N, Bertrand K, et al. Associations of life course obesity with endometrial cancer in the Epidemiology of Endometrial Cancer Consortium (E2C2). Int J Epidemiol. 2023;52:1086-1099.
  19. Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016;34:4225-4230.
  20. Giaquinto NA, Broaddus RR, Jemal A, et al. The changing landscape of gynecologic cancer mortality in the United States. Obstet Gynecol. 2022;139:440-442.
  21. Rauh-Hain JA, Melamed A, Buskwofie A, et al. Adnexal mass in the postmenopausal patient. Clin Obstet Gynecol. 2015;58:53-65.
  22. Wright JD, Fiorelli J, Schiff PB, et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer. 2009;115:1276-85.
  23. Long B, Liu FW, Bristow RE. Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States. Gynecol Oncol. 2013;130:652-659.
  24. Mukerji B, Baptiste C, Chen L, et al. Racial disparities in young women with endometrial cancer. Gynecol Oncol. 2018;148:527-534.
  25. Dolly D, Mihai A, Rimel BJ, et al. A delay from diagnosis to treatment is associated with a decreased overall survival for patients with endometrial cancer. Front Oncol. 2016;12;6:31.
  26. Bregar AJ, Alejandro Rauh-Hain J, Spencer R, et al. Disparities in receipt of care for high-grade endometrial cancer: a National Cancer Database analysis. Gynecol Oncol. 2017;145:114-121.
  27. Sud S, Holmes J, Eblan M, et al. Clinical characteristics associated with racial disparities in endometrial cancer outcomes: a surveillance, epidemiology and end results analysis. Gynecol Oncol. 2018;148:349-356.
  28. Doll KM, Hempstead B, Alson J, et al. Assessment of prediagnostic experiences of Black women with endometrial cancer in the United States. JAMA Netw Open. 2020;3:e204954.
  29. Doll KM, Khor S, Odem-Davis K, at al. Role of bleeding recognition and evaluation in Black-White disparities in endometrial cancer. Am J Obstet Gynecol. 2018;219:593.e1-593.e14.
  30. Huang AB, Huang Y, Hur C, et al. Impact of quality of care on racial disparities in survival for endometrial cancer. Am J Obstet Gynecol. 2020;223:396.e1-396.e13.
  31. Niranjan SJ, Martin MY, Fouad MN, et al. Bias and stereotyping among research and clinical professionals: perspectives on minority recruitment for oncology clinical trials. Cancer. 2020;126:1958-1968.
  32. Penner LA, Dovidio JF, Gonzalez R, et al. The effects of oncologist implicit racial bias in racially discordant oncology interactions. J Clin Oncol. 2016;34:2874-80.
  33. Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5:e191870.
  34. Morton M, Yao M, Chalif J, et al. Clinical trial participation is associated with improved overall survival in patients with platinum-resistant epithelial ovarian cancer. Presented at: 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 25-28, 2023. Abstract 140.
  35. Patel KB, Pyrzak A, Williams H, et al. Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent epithelial ovarian cancer. Presented at: 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 24-27, 2018. Abstract 6.
  36. Niranjan SJ, Wenzel JA, Martin MY, et al. Perceived institutional barriers among clinical and research professionals: minority participation in oncology clinical trials. JCO Oncol Pract. 2021;17:e666-e675.
  37. Guidry JJ, Aday LA, Zhang D, et al. Transportation as a barrier to cancer treatment. Cancer Pract. 1997;5:361-6.
  38. Buskwofie A, Huang Y, Tergas AI, et al. Impact of hospital volume on racial disparities and outcomes for endometrial cancer. Gynecol Oncol. 2018;149:329-336.
  39. Wright JD, Lewin SN, Deutsch I, et al. Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer. Obstet Gynecol. 2011;117:1051-1059.
  40. Diaz AA, Thakur N, Celedón JC. Lessons learned from health disparities in coronavirus disease-2019 in the United States. Clin Chest Med. 2023;44:425-434.